These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 28835423)

  • 1. Cost-effectiveness of age-related macular degeneration study supplements in the UK: combined trial and real-world outcomes data.
    Lee AY; Butt T; Chew E; Agron E; Clemons TE; Egan CA; Lee CS; Tufail A;
    Br J Ophthalmol; 2018 Apr; 102(4):465-472. PubMed ID: 28835423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes.
    Butt T; Lee A; Lee C; Tufail A;
    BMJ Open; 2015 May; 5(5):e006535. PubMed ID: 25943370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model study of AREDS antioxidant supplementation of AMD compared to Visudyne: a dominant strategy?
    Trevithick J; Massel D; Robertson JM; Tomany S; Wall R
    Ophthalmic Epidemiol; 2004 Dec; 11(5):337-46. PubMed ID: 15590581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of anti-oxidant vitamins plus zinc treatment to prevent the progression of intermediate age-related macular degeneration. A Singapore perspective.
    Saxena N; George PP; Heng BH; Lim TH; Yong SO
    Indian J Ophthalmol; 2015 Jun; 63(6):516-23. PubMed ID: 26265643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
    Dakin HA; Wordsworth S; Rogers CA; Abangma G; Raftery J; Harding SP; Lotery AJ; Downes SM; Chakravarthy U; Reeves BC;
    BMJ Open; 2014 Jul; 4(7):e005094. PubMed ID: 25079928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
    Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
    Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
    Butt T; Patel PJ; Tufail A; Rubin GS
    Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
    Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
    Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Screening for Intermediate Age-Related Macular Degeneration during Diabetic Retinopathy Screening.
    Chan CK; Gangwani RA; McGhee SM; Lian J; Wong DS
    Ophthalmology; 2015 Nov; 122(11):2278-85. PubMed ID: 26315045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence of patients with age-related macular degeneration to AREDS 2-recommended nutritional supplements.
    Alghamdi A; Keegan D; Connell P; Dooley I; O'Toole L
    Ir J Med Sci; 2023 Dec; 192(6):3163-3167. PubMed ID: 36971785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of vitamin therapy for age-related macular degeneration.
    Rein DB; Saaddine JB; Wittenborn JS; Wirth KE; Hoerger TJ; Narayan KM; Clemons T; Sorensen SW
    Ophthalmology; 2007 Jul; 114(7):1319-26. PubMed ID: 17320962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35.
    Chew EY; Clemons TE; Agrón E; Sperduto RD; Sangiovanni JP; Kurinij N; Davis MD;
    Ophthalmology; 2013 Aug; 120(8):1604-11.e4. PubMed ID: 23582353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
    Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
    Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current use of dietary supplementation in patients with age-related macular degeneration.
    Chang CW; Chu G; Hinz BJ; Greve MD
    Can J Ophthalmol; 2003 Feb; 38(1):27-32. PubMed ID: 12608514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
    Javitt JC; Zlateva GP; Earnshaw SR; Pleil AM; Graham CN; Brogan AJ; Shah SN; Adamis AP
    Value Health; 2008; 11(4):563-74. PubMed ID: 18179676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing self-reported use of antioxidant supplements in patients with age-related macular degeneration.
    Yu AL; Paul T; Schaumberger M; Welge-Lussen U
    Curr Eye Res; 2014 Dec; 39(12):1240-6. PubMed ID: 24749547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
    Earnshaw SR; Moride Y; Rochon S
    Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom.
    Claxton L; Hodgson R; Taylor M; Malcolm B; Pulikottil Jacob R
    Pharmacoeconomics; 2017 Feb; 35(2):237-248. PubMed ID: 27787744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.
    Hopley C; Salkeld G; Wang JJ; Mitchell P
    Br J Ophthalmol; 2004 Apr; 88(4):450-4. PubMed ID: 15031152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.